Public health - A sound rationale needed for phase IIIHIV-1 vaccine trials

被引：106

作者：

Burton, DR ^{[1
]}

Desrosiers, RC

Doms, RW

Feinberg, MB

Gallo, RC

Hahn, B

Hoxie, JA

Hunter, E

Korber, B

Landay, A

Lederman, MM

Lieberman, J

McCune, JM

Moore, JP

Nathanson, N

Picker, L

Richman, D

Rinaldo, C

Stevenson, M

Watkins, DI

Wolinsky, SM

Zack, JA

机构：

[1] Scripps Res Inst, La Jolla, CA 92037 USA

[2] Harvard Med Sch, Boston, MA USA

[3] Univ Penn, Philadelphia, PA 19104 USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Inst Human Virol, Baltimore, MD USA

[6] Univ Alabama, Birmingham, AL USA

[7] Santa Fe Inst, Santa Fe, NM 87501 USA

[8] Rush Med Coll, Chicago, IL 60612 USA

[9] Case Western Reserve Univ, Cleveland, OH 44106 USA

[10] Gladstone Inst Virol & Immunol, San Francisco, CA USA

[11] Cornell Univ, Weill Med Coll, New York, NY USA

[12] Oregon Hlth & Sci Univ, Portland, OR USA

[13] Univ Calif San Diego, San Diego, CA 92103 USA

[14] San Diego Vet Affairs Healthcare Syst, San Diego, CA USA

[15] Univ Pittsburgh, Pittsburgh, PA USA

[16] Univ Massachusetts, Sch Med, Worcester, MA USA

[17] Univ Wisconsin, Madison, WI USA

[18] Northwestern Univ, Chicago, IL 60611 USA

[19] Univ Calif Los Angeles, Los Angeles, CA USA

来源：

SCIENCE | 2004年 / 303卷 / 5656期

关键词：

D O I：

10.1126/science.1094620

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页码：316 / 316

页数：1

共 8 条

[1] Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults [J].

Clements-Mann, ML ;

Weinhold, K ;

Matthews, TJ ;

Graham, BS ;

Gorse, GJ ;

Keefer, MC ;

McElrath, MJ ;

Hsieh, RH ;

Mestecky, J ;

Zolla-Pazner, S ;

Mascola, J ;

Schwartz, D ;

Siliciano, R ;

Corey, L ;

Wright, PF ;

Belshe, R ;

Dolin, R ;

Jackson, S ;

Xu, S ;

Fast, P ;

Walker, MC ;

Stablein, D ;

Excler, JL ;

Tartaglia, J ;

Duliege, AM ;

Sinangil, F ;

Paoletti, E .

JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (05) :1230-1246

[2]

Cohen J, 2003, SCIENCE, V302, P1309

[3] Public health - AIDS vaccine trial produces disappointment and confusion [J].

Cohen, J .

SCIENCE, 2003, 299 (5611) :1290-1291

[4] Biomedical research - Disappointing data scuttle plans for large-scale AIDS vaccine trial [J].

Cohen, J .

SCIENCE, 2002, 295 (5560) :1616-1617

[5]

Cohen J, 2001, SHOTS DARK WAYWARD S

[6] Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines [J].

Connor, RI ;

Korber, BTM ;

Graham, BS ;

Hahn, BH ;

Ho, DD ;

Walker, BD ;

Neumann, AU ;

Vermund, SH ;

Mestecky, J ;

Jackson, S ;

Fenamore, E ;

Cao, Y ;

Gao, F ;

Kalams, S ;

Kunstman, KJ ;

McDonald, D ;

McWilliams, N ;

Trkola, A ;

Moore, JP ;

Wolinsky, SM .

JOURNAL OF VIROLOGY, 1998, 72 (02) :1552-1576

[7] Cytokine responses to human immunodeficiency virus type I (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1SF-2 recombinant GP120 [J].

Gorse, GJ ;

Patel, GB ;

Mandava, MD ;

Arbuckle, JA ;

Doyle, TM ;

Belshe, RB .

VACCINE, 2001, 19 (13-14) :1806-1819

[8] Comparison between Env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults [J].

Ratto-Kim, S ;

Loomis-Price, LD ;

Aronson, N ;

Grimes, J ;

Hill, C ;

Williams, C ;

El Habib, R ;

Birx, DL ;

Kim, JH .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (01) :9-17

← 1 →